Interactions between the cytochrome P450 system and the second-generation antipsychotics

Prior, Trevor I.; Baker, Glen B.
March 2003
Journal of Psychiatry & Neuroscience;Mar2003, Vol. 28 Issue 2, p99
Academic Journal
Awareness of the metabolism of second-generation antipsychotics by the cytochrome P450 (CYP) system can inform the clinician about how to avoid and manage drug-drug interactions involving these enzymes. Clozapine is metabolized primarily by CYPIA2, with additional contributions by CYP2CI9, CYP2D6 and CYP3A4. Risperidone is metabolized primarily by CYP2D6 and to a lesser extent by CYP3A4. Olanzapine is metabolized primarily by CYPIA2 and to a lesser extent by CYP2D6. Quetiapine and ziprasidone are metabolized by CYP3A4. At the usual clinical doses, these drugs appear not to significantly affect the metabolism of other medications. There is, however, a lack of in vivo metabolic data, especially for the 3 newest second-generation antipsychotics: olanzapine, quetiapine and ziprasidone.


Related Articles

  • Cytochrome P450 Phenotyping/Genotyping in Patients Receiving Antipsychotics: Useful Aid to Prescribing? Dahl, M-L. // Clinical Pharmacokinetics;May2002, Vol. 41 Issue 7, p453 

    Many antipsychotics, including perphenazine, zuclopenthixol, thioridazine, haloperidol and risperidone, are metabolised to a significant extent by the polymorphic cytochrome P450 (CYP) 2D6, which shows large interindividual variation in activity. Significant relationships between CYP2D6 genotype...

  • Fatal intoxication cases: cytochromeP 4502D6 and 2C19 genotype distributions. Zackrisson, A.L.; Holmgren, P.; Gladh, A.B.; Ahlner, J.; Lindblom, B. // European Journal of Clinical Pharmacology;Oct2004, Vol. 60 Issue 8, p547 

    Objective: Many commonly used pharmaceuticals, such as antidepressants and neuroleptics as well as some illegal drugs, are metabolised by the cytochrome P 450 enzyme debrisoquine 4-hydroxylase (CYP2D6). Of Caucasians, 7-10% lack this enzyme, which can, upon administration of drugs in normal...

  • An Evaluation of Ondansetron Binding Interactions with Human Cytochrome P450 Enzymes CYP3A4 and CYP2D6. Lewis, David F. V.; Ito, Yuko; Eddershaw, Peter J.; Dickins, Maurice; Goldfarb, Peter S. // Drug Metabolism Letters;Jan2010, Vol. 4 Issue 1, p25 

    The results of an evaluation study of ondansetron binding to human cytochromes P450 CYP3A4 and CYP2D6 is reported. The methodology includes NMR spectroscopic measurements of substrate to heme iron distances together with molecular modelling of the enzyme-substrate interactions. It is shown that...

  • Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance. Shu-Feng Zhou // Clinical Pharmacokinetics;2009, Vol. 48 Issue 11, p689 

    Cytochrome P450 (CYP) 2D6 is one of the most investigated CYPs in relation to genetic polymorphism, but accounts for only a small percentage of all hepatic CYPs (~2-4%). There is a large interindividual variation in the enzyme activity of CYP2D6. The enzyme is largely non-inducible and...

  • Metabolism of Atypical Antipsychotics: Involvement of Cytochrome P450 Enzymes and Relevance for Drug-Drug Interactions. Urichuk, Liana; Prior, Trevor I.; Dursun, Serdaqr; Baker, Glen // Current Drug Metabolism;Jun2008, Vol. 9 Issue 5, p410 

    The involvement of cytochrome P450 (CYP) enzymes in the metabolism of the atypical (second-generation) antipsychotics clozapine, risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, paliperidone and amisulpride is reviewed, and the possible relevance of this metabolism to drug-drug...

  • Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole. Hendset, Magnhild; Hermann, Monica; Lunde, Hilde; Refsum, Helge; Molden, Espen // European Journal of Clinical Pharmacology;Dec2007, Vol. 63 Issue 12, p1147 

    Aripiprazole is an atypical antipsychotic drug which is metabolized by the polymorphic enzyme cytochrome P450 2D6 (CYP2D6). The aim of the present study was to investigate the impact of the CYP2D6 genotype on serum concentrations of aripiprazole (ARI) and to determine the sum of ARI and the...

  • Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to cost-effectiveness of pretreatment CYP2D6 screening? Laika, B.; Leucht, S.; Heres, S.; Steimer, W. // Pharmacogenomics Journal;Dec2009, Vol. 9 Issue 6, p395 

    The cytochrome P450 2D6 (CYP2D6) isoenzyme metabolizes about 25% of clinically used drugs. The impact of CYP2D6 metabolizer status on therapeutic outcome was assessed in 365 psychiatric in-patients treated with neuroleptics or antidepressants. Length of hospitalization and response onset were...

  • Clinically Significant Drug Interactions with Atypical Antipsychotics. Kennedy, William Klugh; Jann, Michael W.; Kutscher, Eric C. // CNS Drugs;Dec2013, Vol. 27 Issue 12, p1021 

    Atypical antipsychotics [also known as second-generation antipsychotics (SGAs)] have become a mainstay therapeutic treatment intervention for patients with schizophrenia, bipolar disorders and other psychotic conditions. These agents are commonly used with other medications—most notably,...

  • CYP-Mediated Clozapine Interactions: How Predictable Are They? Chetty, Manoranjenni; Murray, Michael // Current Drug Metabolism;May2007, Vol. 8 Issue 4, p307 

    Despite the introduction of newer drugs, the atypical antipsychotic clozapine remains the most effective drug in psychotic patients who are resistant to treatment with conventional agents. Optimal therapeutic responses to clozapine have been reported with serum concentrations between 350 μg/L...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics